Metraipolis › archive › dc_85d2e4a36e32
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42521925
- DOI
- 10.1186/s43046-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-17T11:27:49.542Z
- SHA-256 of the archived text
54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c- Stable URL of this page
https://metraipolis.com/documento/dc_85d2e4a36e32
How to cite
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925 — Europe PMC (en), https://europepmc.org/article/MED/42521925 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_85d2e4a36e32 (Metraipolis archive dc_85d2e4a36e32, sha256 54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c)
BibTeX
@misc{dc85d2e4a36e32,
title = {Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience — Europe PMC PMID:42521925},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42521925},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_85d2e4a36e32; sha256 54664dfcecea9a2f3783073fdf0d855fb7827459e7d917acbb3a4200b0b78e8c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42521925. Agents can read the archived copy with the MCP tool read_document.